Retrieve available abstracts of 62 articles: HTML format
Single Articles
January 2025
LEE B, Chang SJ, Kwon BS, Son JH, et al Correction: Impact of PARP inhibitor maintenance therapy in newly diagnosed
advanced epithelial ovarian cancer: A meta-analysis.
PLoS One. 2025;20:e0317158. PubMedAbstract available
TJOKROPRAWIRO BA, Novitasari K, Ulhaq RA, Sulistya HA, et al Investigation of the trends and associated factors of ovarian cancer in
Indonesia: A systematic analysis of the Global Burden of Disease study 1990-2021.
PLoS One. 2025;20:e0313418. PubMedAbstract available
TAL O, Zahavi T, Sinberger LA, Salmon-Divon M, et al Unlocking prognostic potential: A genomic signature of caloric restriction in
patients with epithelial ovarian cancer.
PLoS One. 2025;20:e0317502. PubMedAbstract available
ZHANG J, Gangwar S, Bano N, Ahmad S, et al Probing the role of Coniferin and Tetrahydrocurcumin from Traditional Chinese
medicine against PSAT1 in early-stage ovarian cancer: An in silico study.
PLoS One. 2025;20:e0313585. PubMedAbstract available
LI S, Wang Z, Huang HD Deciphering ovarian cancer heterogeneity through spatial transcriptomics,
single-cell profiling, and copy number variations.
PLoS One. 2025;20:e0317115. PubMedAbstract available
ALIZADEH H, Kerachian S, Babashah S, Soltani BM, et al Introduction of AGPAT3 gene as a regulator of cisplatin resistance in A2780
ovarian endometrioid carcinoma cell line.
PLoS One. 2025;20:e0318740. PubMedAbstract available
DE AMORIM IFG, Melo CPS, Pereira RA, Cunha SM, et al Association of a CHEK2 somatic variant with tumor microenvironment calprotectin
expression predicts platinum resistance in a small cohort of ovarian carcinoma.
PLoS One. 2025;20:e0315487. PubMedAbstract available
BAO Q, Wang Z, Yang T, Su X, et al Curcumin induces mitochondrial dysfunction-associated oxidative DNA damage in
ovarian cancer cells.
PLoS One. 2025;20:e0319846. PubMedAbstract available
January 2024
YOO MY, Woo KJ, Kang SY, Moon BS, et al Efficacy of preoperative lymphoscintigraphy in predicting surgical outcomes of
lymphaticovenous anastomosis in lower extremity lymphedema: Clinical correlations
in gynecological cancer-related lymphedema.
PLoS One. 2024;19:e0296466. PubMedAbstract available
WANG G, Fu J, Liu M, Zheng Q, et al CXC chemokines: Potential biomarker and immunotherapeutic target for uterine
corpus endometrial carcinoma.
PLoS One. 2024;19:e0277872. PubMedAbstract available
Expression of Concern: Minocycline Suppresses Interleukine-6, Its Receptor System
and Signaling Pathways and Impairs Migration, Invasion and Adhesion Capacity of
Ovarian Cancer Cells: In Vitro and In Vivo Studies.
PLoS One. 2024;19:e0298444. PubMed
YONG CM, Yehgambaram PAP, Lee SWH Cost-effectiveness analysis of olaparib maintenance therapy for BRCA mutation
ovarian cancer in the public sector in Malaysia.
PLoS One. 2024;19:e0298130. PubMedAbstract available
DING H, Hu B, Guo R Comprehensive analysis of single cell and bulk data develops a promising
prognostic signature for improving immunotherapy responses in ovarian cancer.
PLoS One. 2024;19:e0298125. PubMedAbstract available
MIKHAEL S, Kurdi A, Khoueiry-Zgheib N, Tahtouh R, et al Evaluating synergistic effects of metformin and simvastatin on ovarian cancer
cells.
PLoS One. 2024;19:e0298127. PubMedAbstract available
KANG J, Na K, Kang H, Cho U, et al Prediction of homologous recombination deficiency from Oncomine Comprehensive
Assay Plus correlating with SOPHiA DDM HRD Solution.
PLoS One. 2024;19:e0298128. PubMedAbstract available
LI L, He L, Guo W, Ma J, et al PMFFNet: A hybrid network based on feature pyramid for ovarian tumor
segmentation.
PLoS One. 2024;19:e0299360. PubMedAbstract available
CHEN Z, Wang C, Ding J, Yu T, et al Construction and analysis of competitive endogenous RNA networks and prognostic
models associated with ovarian cancer based on the exoRBase database.
PLoS One. 2024;19:e0291149. PubMedAbstract available
MEHRA T, Lupatsch JE, Kossler T, Dedes K, et al Olaparib not cost-effective as maintenance therapy for platinum-sensitive,
BRCA1/2 germline-mutated metastatic pancreatic cancer.
PLoS One. 2024;19:e0301271. PubMedAbstract available
LI N, Jin S, Wu J, Ji H, et al Effect of different treatment modalities on ovarian cancer patients with liver
metastases: A retrospective cohort study based on SEER.
PLoS One. 2024;19:e0299504. PubMedAbstract available
REID F, Adams T, Adel RS, Andrade CE, et al The every woman study low- and middle-income countries edition protocol: A
multi-country observational study to assess opportunities and challenges to
improving survival and quality of life for women with ovarian cancer.
PLoS One. 2024;19:e0298154. PubMedAbstract available
PARK K, Kwon JY, Song JM, Pyeon SY, et al Prognostic impact of suspicious extraabdominal lymph nodes on patient survival in
advanced ovarian cancer.
PLoS One. 2024;19:e0299205. PubMedAbstract available
HOSOKAWA S, Norimatsu Y, Shinagawa A, Kurokawa T, et al Assessment of the localization of chondroitin sulfate in various types of
endometrial carcinoma.
PLoS One. 2024;19:e0304420. PubMedAbstract available
KIM NK, Suh DH, Kim K, No JH, et al High-throughput viable circulating tumor cell isolation using tapered-slit
membrane filter-based chipsets in the differential diagnosis of ovarian tumors.
PLoS One. 2024;19:e0304704. PubMedAbstract available
KARSTENSEN S, Kaiser K, Moos C, Poulsen TS, et al DNA alterations in ovarian adult granulosa cell tumours: A scoping review
protocol.
PLoS One. 2024;19:e0303989. PubMedAbstract available
NUNEZ-RIOS JD, Reyna-Jeldes M, Mata-Martinez E, Campos-Contreras ADR, et al Extracellular ATP/P2X7 receptor, a regulatory axis of migration in ovarian
carcinoma-derived cells.
PLoS One. 2024;19:e0304062. PubMedAbstract available
JANG DH, Lee HG, Lee B, Kang S, et al Prediction of final pathology depending on preoperative myometrial invasion and
grade assessment in low-risk endometrial cancer patients: A Korean Gynecologic
Oncology Group ancillary study.
PLoS One. 2024;19:e0305360. PubMedAbstract available
ZHAO S, Wang L, Ouyang M, Xing S, et al Polyploid giant cancer cells induced by Docetaxel exhibit a senescence phenotype
with the expression of stem cell markers in ovarian cancer cells.
PLoS One. 2024;19:e0306969. PubMedAbstract available
ANCHOORI RK, Tseng SH, Tsai HL, Palande V, et al Preclinical studies of RA475, a guanidine-substituted spirocyclic candidate
RPN13/ADRM1 inhibitor for treatment of ovarian cancer.
PLoS One. 2024;19:e0305710. PubMedAbstract available
MA MC, Lavi ES, Altwerger G, Lin ZP, et al Predictive modeling of gene mutations for the survival outcomes of epithelial
ovarian cancer patients.
PLoS One. 2024;19:e0305273. PubMedAbstract available
CARTER R, Petrik JJ, Moorehead RA Overexpression of miR-200s inhibits proliferation and invasion while increasing
apoptosis in murine ovarian cancer cells.
PLoS One. 2024;19:e0307178. PubMedAbstract available
PATRA A, Ali SS, Devi NM, Qadeer AS, et al Prevalence of BRCA mutation in breast and ovarian cancer among women in India: A
systematic review and meta-analysis protocol.
PLoS One. 2024;19:e0306612. PubMedAbstract available
TANG F, Hummitzsch K, Rodgers RJ Unique features of KGN granulosa-like tumour cells in the regulation of
steroidogenic and antioxidant genes.
PLoS One. 2024;19:e0308168. PubMedAbstract available
HOLMLUND S, Collins E, Lalos A, Idahl A, et al From symptoms to surgery-A pathway through uncertainty and hope: An interview
study of women facing ovarian surgery.
PLoS One. 2024;19:e0307666. PubMedAbstract available
ISINGIZWE ZR, Mortan LF, Benbrook DM Platelet and epithelial cell interations can be modeled in cell culture, and are
not affected by dihomo-gamma-linolenic acid.
PLoS One. 2024;19:e0309125. PubMedAbstract available
KAUTZ-FREIMUTH S, Lautz Z, Shukri A, Redaelli M, et al Decisional conflict and knowledge in women with BRCA1/2 pathogenic variants: An
exploratory age group analysis of a randomised controlled decision aid trial.
PLoS One. 2024;19:e0311432. PubMedAbstract available
YOSHIDA-COURT K, Karpinets TV, Mitra A, Solley TN, et al Correction: Immune environment and antigen specificity of the T cell receptor
repertoire of malignant ascites in ovarian cancer.
PLoS One. 2024;19:e0314643. PubMedAbstract available
MOGI K, Yoshihara M, Emoto R, Miyamoto E, et al Histology-specific long-term oncologic outcomes in patients with epithelial
ovarian cancer who underwent complete tumor resection: The implication of occult
seeds after initial surgery.
PLoS One. 2024;19:e0311421. PubMedAbstract available
KIM K, Khazan N, McDowell JL, Snyder CWA, et al The NF-kappaB-HE4 axis: A novel regulator of HE4 secretion in ovarian cancer.
PLoS One. 2024;19:e0314564. PubMedAbstract available
WEINSTEIN SJ, Parisi D, Mondul AM, Layne TM, et al Vitamin D binding protein genetic isoforms, serum vitamin D, and cancer risk in
the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
PLoS One. 2024;19:e0315252. PubMedAbstract available
RUSSO D, Spina A, Portella L, Bello AM, et al The CXCR4 antagonist R54 targets epithelial-mesenchymal transition (EMT) in human
ovarian cancer cells.
PLoS One. 2024;19:e0314735. PubMedAbstract available
PERAMPALAM P, McDonald JI, Dick FA GO-CRISPR: A highly controlled workflow to discover gene essentiality in
loss-of-function screens.
PLoS One. 2024;19:e0315923. PubMedAbstract available
SENGUPTA D, Ali SN, Bhattacharya A, Mustafi J, et al Correction: A deep hybrid learning pipeline for accurate diagnosis of ovarian
cancer based on nuclear morphology.
PLoS One. 2024;19:e0316114. PubMedAbstract available
WANG H, Han X, Niu S, Cheng H, et al DFASGCNS: A prognostic model for ovarian cancer prediction based on dual fusion
channels and stacked graph convolution.
PLoS One. 2024;19:e0315924. PubMedAbstract available
LOPACINSKA-JORGENSEN J, Oliveira DVNP, Novotny GW, Hogdall CK, et al Correction: Integrated microRNA and mRNA signatures associated with overall
survival in epithelial ovarian cancer.
PLoS One. 2024;19:e0315859. PubMedAbstract available
January 2023
HAWARDEN A, Price M, Russell B, Wilson G, et al A three protein signature fails to externally validate as a biomarker to predict
surgical outcome in high-grade epithelial ovarian cancer.
PLoS One. 2023;18:e0281798. PubMedAbstract available
JLASSI A, Manai M, Morjen M, Sahraoui G, et al VISTA+/CD8+ status correlates with favorable prognosis in Epithelial ovarian
cancer.
PLoS One. 2023;18:e0278849. PubMedAbstract available
EBRING C, Marlin R, Macni J, Vallard A, et al Type II endometrial cancer: Incidence, overall and disease-free survival in
Martinique.
PLoS One. 2023;18:e0278757. PubMedAbstract available
NUNES PEREIRA P, Francoise Derchain S, Yoshida A, Hoelz de Oliveira Barros R, et al Diffusion-weighted magnetic resonance sequence and CA125/CEA ratio can be used as
add-on tools to ultrasound for the differentiation of ovarian from non-ovarian
pelvic masses.
PLoS One. 2023;18:e0283212. PubMedAbstract available
GOLDSBURY DE, Vassallo A, Weber MF, Steinberg J, et al Health services costs for ovarian cancer in Australia: Estimates from the 45 and
Up Study.
PLoS One. 2023;18:e0282851. PubMedAbstract available
KIM NK, Suh DH, Kim K, Kim YB, et al Feasibility of extended cycles of neoadjuvant chemotherapy in patients with
advanced ovarian cancer in terms of prognosis and surgical outcomes.
PLoS One. 2023;18:e0284753. PubMedAbstract available
LOPACINSKA-JORGENSEN J, Petersen PHD, Oliveira DVNP, Hogdall CK, et al Strategies for data normalization and missing data imputation and consequences
for potential diagnostic microRNA biomarkers in epithelial ovarian cancer.
PLoS One. 2023;18:e0282576. PubMedAbstract available
Expression of Concern: Neoadjuvant chemotherapy versus primary debulking surgery
in advanced epithelial ovarian cancer: A meta-analysis of peri-operative outcome.
PLoS One. 2023;18:e0285545. PubMed
WU X, Lu W, Jiang C, Zhang D, et al Effect of ERCC1 polymorphisms on the response to platinum-based chemotherapy: A
systematic review and meta-analysis based on Asian population.
PLoS One. 2023;18:e0284825. PubMedAbstract available
ANCHOORI RK, Anchoori V, Lam B, Tseng SH, et al Development and anticancer properties of Up284, a spirocyclic candidate
ADRM1/RPN13 inhibitor.
PLoS One. 2023;18:e0285221. PubMedAbstract available
LIU H, Ma S, Chen X, Wu H, et al Diagnostic accuracy of the Copenhagen Index in ovarian malignancy: A
meta-analysis.
PLoS One. 2023;18:e0286650. PubMedAbstract available
CHEN B, Lu X, Zhou Q, Chen Q, et al PAXIP1-AS1 is associated with immune infiltration and predicts poor prognosis in
ovarian cancer.
PLoS One. 2023;18:e0290031. PubMedAbstract available
MOATAMED NA, Vahdatshariatpanahi S, Gjertson DW, Sachs CR, et al Androgen receptor and its correlation with estrogen and progesterone receptors,
aimed for identification of cases for future anti-androgen therapy in endometrial
cancers.
PLoS One. 2023;18:e0291361. PubMedAbstract available
MUHAMMAD S, Azwan RJ, Rita RS, Susanti R, et al The Role of Interleukin 6 (IL6), Cancer Antigen-125 (CA-125), and Human
Epididymis Protein 4 (HE4) to predict tumor resectability in the advanced
epithelial ovarian cancer patients.
PLoS One. 2023;18:e0292282. PubMedAbstract available
LEE B, Chang SJ, Kwon BS, Son JH, et al Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced
epithelial ovarian cancer: A meta-analysis.
PLoS One. 2023;18:e0294647. PubMedAbstract available
ROBERTSON SE, Yasukawa M, Marchion DC, Xiong Y, et al Prevalence of viral DNA in high-grade serous epithelial ovarian cancer and
correlation with clinical outcomes.
PLoS One. 2023;18:e0294448. PubMedAbstract available
Retraction: SOX2 Enhances the Migration and Invasion of Ovarian Cancer Cells via
Src Kinase.
PLoS One. 2023;18:e0295163. PubMed
TAO F, Ruan S, Liu W, Wang L, et al Correction: Fuling Granule, a Traditional Chinese Medicine Compound, Suppresses
Cell Proliferation and TGFbeta-Induced EMT in Ovarian Cancer.
PLoS One. 2023;18:e0296410. PubMedAbstract available